Ringly Raises $5.1 Million Led By Andreessen Horowitz To Expand Its Smart Jewelry Collection Beyond Rings
Context & Ripple Effects
In January 2015, Ringly's $5.1 million round — led by Andreessen Horowitz — was one of the earliest sizable bets on the smart-ring form factor, with the startup positioning connected jewelry as a fashion accessory first and expanding beyond rings into the rest of a wearer's collection.
The decade of coverage since shows where that category ended up: Oura went from selling 150K rings around its $28M Series B in 2020 to a $75M Series D backed by medical device maker Dexcom and ultimately a roughly $900M raise at an approximately $11B valuation, while Bengaluru-based Ultrahuman raised $35M for the same wrist-free form factor.
First-order effects
- Ringly gains capital and Andreessen Horowitz's network to push smart jewelry past rings into bracelets and necklaces, betting that design and aesthetics — not sensor depth — are what get women to wear connected devices.
Second-order effects
- The money trail shows which differentiation won: later rounds in the category were driven by health credibility — Google's Gradient Ventures, Square, and Forerunner backing Oura, then Dexcom investing directly — rather than by fashion pedigree, forcing any fashion-led player to either add real biometric capability or cede the category.
Third-order effects
- If the pattern holds, the ring/jewelry form factor consolidates into a health-hardware platform business — with device makers partnering into clinical ecosystems (as the Dexcom-backed round signals) — leaving purely decorative smart jewelry a niche rather than a venture-scale category.
The trend: Consumer wearables migrated over the decade from fashion-led smart jewelry toward medically credible health rings, with valuations scaling from single-digit millions to billions as clinical partners replaced style as the draw.